Sandu Pharmaceuticals Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue in Q2 2023 saw a robust increase to ₹17.66 crore, indicating strong market demand.
Net profit jumped to ₹0.55 crore in Q3 2023, up from ₹0.11 crore in Q2 2023, showcasing profitability recovery.
Operating profit margin improved significantly to 4.08% in Q3 2023, reflecting better cost management.

NEGATIVES

Revenue decreased to ₹16.61 crore in Q3 2023 from ₹17.66 crore in Q2 2023, indicating potential market fluctuations.
Net profit declined to ₹0.21 crore in Q4 2023, down from ₹0.55 crore in Q3 2023, raising concerns about sustainability.
Material costs rose sharply in Q3 2023, impacting overall profitability despite higher revenue.

Field	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24
Revenue	17.09	15.27	17.66	16.61	17.43	15.60	17.04	17.71
Expenses	16.42	14.93	17.45	15.93	17.08	15.19	16.82	17
Operating Profit	0.67	0.33	0.21	0.68	0.35	0.41	0.23	0.71
Other Income	0.03	0.04	0	0.09	0.03	0.31	0.04	0.03
Interest	0.02	0.02	0.02	0.01	0.02	0.01	0.02	0.03
Depreciation	0.13	0.13	0.12	0.13	0.14	0.19	0.16	0.17
Profit Before Tax	0.70	0.38	0.21	0.76	0.38	0.72	0.27	0.74
Tax	0.22	0.11	0.10	0.21	0.17	0.12	0.11	0.24
Net Profit	0.48	0.27	0.11	0.55	0.21	0.59	0.17	0.49
Eps in Rs	0.51	0.26	0.11	0.57	0.21	0.62	0.17	1.95